SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 17.04 millions was observed as compared to Rs. 0.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -16.28 millions as compared to Net Loss of Rs. -9.58 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 further decreased to -17.20% as compared to -3.35% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 17.04 0.00 0.00 71.55 0.00 0.00 10.04 3.95 154.18
Other Income 0.24 0.00 0.00 2.36 0.00 0.00 2.86 1.66 72.29
PBIDT -17.20 -3.35 413.43 -35.98 -6.86 424.49 -19.36 -11.02 75.68
Interest 2.97 3.97 -25.19 9.42 8.92 5.61 12.14 9.00 34.89
PBDT -20.17 -7.32 175.55 -45.40 -15.78 187.71 -31.50 -20.02 57.34
Depreciation 1.83 1.54 18.83 5.38 4.62 16.45 15.73 6.16 155.36
PBT -22.00 -8.86 148.31 -50.78 -20.40 148.92 -47.23 -26.18 80.40
TAX -5.72 0.72 -894.44 -4.76 -2.51 89.64 10.94 -17.29 -163.27
Deferred Tax -5.72 0.72 -894.44 -4.76 -2.51 89.64 21.47 -17.29 -224.18
PAT -16.28 -9.58 69.94 -46.02 -17.89 157.24 -58.17 -8.89 554.33
Equity 93.80 73.59 27.46 93.80 73.59 27.46 73.59 73.59 0.00
PBIDTM(%) -100.94 0.00 0.00 -50.29 0.00 0.00 -192.83 -278.99 -30.88

Vista Pharma Share Price

7.70 0.51 (7.09%)
22-Apr-2026 11:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1659.55
Dr. Reddys Lab 1219.60
Cipla 1233.30
Zydus Lifesciences 930.25
Lupin 2308.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×